Membership Level
Company Headquarters
1 DNA Way, South San Francisco, CA 94080
Contact Name
Tony Honingford


Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit

About Genentech in Cancer Immunotherapy 

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system. 

About Genentech in Personalized Healthcare 

For more than 20 years, Genentech has helped lay the scientific groundwork for personalized healthcare with treatments that target the underlying biology of cancer and other diseases. Now, with profound changes in data and technology transforming how medicines are discovered, developed and delivered to patients, we are uniquely positioned to extend this approach across all of healthcare. With our ability to integrate research and development, personalized diagnosis, disease monitoring and treatment access, we are advancing personalized healthcare for every aspect of the patient experience. 

Our strategy is rooted in groundbreaking science that can accelerate drug discovery and development. We are also leveraging technologies such as real-world datasets, artificial intelligence, genomic profiling and digital health across our therapeutic portfolio, with an initial emphasis on oncology, neurology, ophthalmology and diagnostics. Through collaborations with academic institutions, industry partners, patients, physicians and regulatory agencies, our goal is to dramatically improve the performance of the entire healthcare ecosystem and the lives of every patient. 

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously. Learn about our response to COVID-19.

Patient Assistance Programs

About Genentech Access Solutions 

Access Solutions is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who 

are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 2 million patients access the medicines they need. 

Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit this page for more information.

About Genentech Oncology Co-Pay Card Assistance Program 

Eligible patients may pay as little as $5 per treatment for their co-pay or co-insurance depending on their health insurance plan. Additionally, eligible patients can receive up to $25,000 in assistance per 12-month period for medicine costs. If a patient is taking more than one Genentech cancer medicine, these benefits apply to each medicine individually.

Our Products

Infused Products

Avastin® (bevacizumab)
GAZYVA® (obinutuzumab)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
KADCYLA® (ado-trastuzumab emtansine)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
POLIVY® (polatuzumab vedotin-piiq)
RITUXAN® (rituximab)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
TECENTRIQ® (atezolizumab)

Oral Products

ALECENSA® (alectinib)
COTELLIC® (cobimetinib)Erivedge® (vismodegib)
GAVRETO® (pralsetinib)
ROZLYTREK® (entrectinib)
VENCLEXTA® (venetoclax)
XELODA® (capecitabine)
ZELBORAF® (vemurafenib)

© 2021 FLASCO | Premium Website Design by The HDG